(0)
WILLINGTON, England, April 8, 2021 /PRNewswire/ Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to fulfil the special need of a patient can be supported.
JZP-458 provides a further therapy option for paediatric and adult patients with ALL or LBL who have not tolerated certain asparaginase treatments and currently have limited treatment options, and we re pleased to support this program, said
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
WILLINGTON, England, April 8, 2021 /PRNewswire/ Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to fulfil the special need of a patient can be supported. JZP 458 provides a further therapy option for paediatric and adult patients with ALL or LBL who have not tolerated certain asparaginase treatments and currently have limited treatment options, and we re pleased to support this program, said
Global Phase 3 D-LIVR study enrollment completion planned in 2021
Peginterferon Lambda for HDV
Global Phase 3 LIMT-2 study initiation planned in 2021
Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
U.S. commercial launch in January 2021
EMA decision expected in 2H21
Lambda for COVID-19
Lancet Respiratory Medicine (Feld et al, 2021)
Considering strategic options to advance program
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Positive Phase 2 PREVENT study published in
JCEM (Craig et al, 2021)
Corporate
Pro-forma cash, cash equivalents and investments of $176.2M, including $128.8M as of December 31, 2020 plus $47.4M from net PRV sale proceeds received in January 2021, expected to fund planned operations through Q4 2023
Fourth Quarter and Full Year 2020 Financial Results
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021
- Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021
- Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 9, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update. In 2021, we plan to achieve important, value creating milestones in both of our HDV clinical programs, said David Cory, President and CEO of Eiger. We will complete enrollment of the Phase 3 D-LIVR study of Lonafarnib, the first and only oral agent in development
Article content
When Alex Johnston and Ryan Fengstad heard the government of Alberta would be funding the gene therapy drug Zolgensma, they felt a weight lift off their shoulders.
“We’ve gotten a lot of tough news and this past year, with Zolgensma specifically, it just felt like there have been a lot of closed doors in our faces, and it really felt like Reign was getting left behind. With this new announcement we were so excited, we were overjoyed, we were crying watching the announcement with [Alberta Health Minister] Tyler Shandro,” Johnston said.
We apologize, but this video has failed to load.